Top Line:Prescription de-escalation to 60 Gy remains an intriguing, albeit investigational, strategy for early-stage p16+ oSCC.
The Study:A post hoc comparison of a collective 59 patients receiving definitive radiation for T1-2 p16+ oropharyngeal squamous cell carcinoma on ORATOR (70 Gy typically concurrent to q3-week cisplatin) and ORATOR2!https://quadshotnews.com/tor-reform/ (60 Gy typically concurrent to weekly cisplatin) compared patient-reported outcomes, toxicity, and survival. First up, Acute grade 2-3 dysphagia and mucositis were significantly lower with 60 Gy. At one year, the 60 Gy cohort reported significantly better swallowing-related quality-of-life, including superior MDADI total (+1.9 vs. -5.8, p=0.035) and functional scores (+5.5 vs. -3.3, p=0.023). The de-escalated cohort also fared better across multiple EORTC domains with less xerostomia, sticky saliva, fatigue, pain, and cough. Finally, rates of progression-free and overall survival at 3 years exceeded 95% in both groups, although the analysis was underpowered for oncologic endpoints.
TBL: Even in a post HN-005 world, “there may be a select population of low-risk patients with HPV-related oropharyngeal carcinomas [read: T1-2, N0-2 with smaller resectable tumors, no evidence of extranodal extension, and minimal to no smoking history] who will benefit from reduction in radiation dose associated with less toxicity but no compromise in survival outcomes.” | Dang, Int J Radiat Oncol Biol Phys 2026
The Study:A post hoc comparison of a collective 59 patients receiving definitive radiation for T1-2 p16+ oropharyngeal squamous cell carcinoma on ORATOR (70 Gy typically concurrent to q3-week cisplatin) and ORATOR2!https://quadshotnews.com/tor-reform/ (60 Gy typically concurrent to weekly cisplatin) compared patient-reported outcomes, toxicity, and survival. First up, Acute grade 2-3 dysphagia and mucositis were significantly lower with 60 Gy. At one year, the 60 Gy cohort reported significantly better swallowing-related quality-of-life, including superior MDADI total (+1.9 vs. -5.8, p=0.035) and functional scores (+5.5 vs. -3.3, p=0.023). The de-escalated cohort also fared better across multiple EORTC domains with less xerostomia, sticky saliva, fatigue, pain, and cough. Finally, rates of progression-free and overall survival at 3 years exceeded 95% in both groups, although the analysis was underpowered for oncologic endpoints.
TBL: Even in a post HN-005 world, “there may be a select population of low-risk patients with HPV-related oropharyngeal carcinomas [read: T1-2, N0-2 with smaller resectable tumors, no evidence of extranodal extension, and minimal to no smoking history] who will benefit from reduction in radiation dose associated with less toxicity but no compromise in survival outcomes.” | Dang, Int J Radiat Oncol Biol Phys 2026